The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Treatment predictors of a sustained virologic response in hepatitis B and C
Open accessAbstract
Treatment predictors are important tools for the management of therapy in patients with chronic hepatitis B and C virus (HBV, HCV) infection. In chronic hepatitis B, several pretreatment parameters have been identified for prediction of virologic response to interferon alfa-based antiviral therapies or treatment with polymerase inhibitors. In interferon alfa and pegylated interferon alfa-treated patients, low baseline HBV DNA concentrations, HBV genotype A (B), and high baseline ALT levels are significantly associated with treatment response. In patients treated with nucleos(t)ide analogues, low baseline HBV DNA but not viral genotype is positively associated with virologic response. During treatment the best predictor of response is HBV DNA kinetics. Early viral suppression is associated with favourable virologic response and reduced risk for subsequent resistance mutations. For the current standard treatment with pegylated interferon alfa and ribavirin in patients with chronic hepatitis C, infection with HCV genotypes 2 and 3, baseline viral load below 400,000-800,000 IU/ml, Asian and Caucasian ethnicity, younger age, low GGT levels, absence of advanced fibrosis/cirrhosis, and absence of steatosis in the liver have been identified as independent pretreatment predictors of a sustained virologic response. After initiation of treatment, initial viral decline with undetectable HCV-RNA at week 4 of therapy (RVR) is the best predictor of sustained virologic response independent of HCV genotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Natural history of liver fibrosis progression in patients with chronic hepatitis C
Poynard, T., Bedossa, P., & Opolon, P. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07642-8 · Cited by 3,011
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Neumann, A. U., Lam, N. P., Dahari, H., Gretch, D. R., Wiley, T. E., Layden, T. J., & Perelson, A. S. (1998) · Science · doi:10.1126/science.282.5386.103 · Cited by 2,113
Schaff, Z., & Csmos, G. (1994) · Cited by 1,868
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Lai, C. L., Ratziu, V., Yuen, M.-F., & Poynard, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)15108-2 · Cited by 1,727
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
Iloeje, U. H., Yang, H., Su, J., Jen, C., You, S., & Chen, C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.016 · Cited by 1,528
Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B
Lau, G. K. K., Piratvisuth, T., Luo, K. X., Marcellin, P., Thongsawat, S., Cooksley, G., Gane, E., Fried, M. W., Chow, W. C., Paik, S. W., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043470 · Cited by 1,519
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Natural history of chronic hepatitis C
Seeff, L. B. (2002) · Hepatology · doi:10.1053/jhep.2002.36806 · Cited by 1,424
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
Torriani, F. J., Rodriguez-Torres, M., Rockstroh, J. K., Lissen, E., Gonzalez-García, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040842 · Cited by 1,233
Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411702 · Cited by 1,226
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., Vidaud, M., Bricaire, F., Opolon, P., Katlama, C., et al. (1999) · Hepatology · doi:10.1002/hep.510300409 · Cited by 1,219
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Janssen, H. L., van Zonneveld, M., Senturk, H., Zeuzem, S., Akarca, U. S., Cakaloglu, Y., Simon, C., So, T. M., Gerken, G., de Man, R. A., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17701-0 · Cited by 1,162
Marcellin, P., Lau, G. K. K., Bonino, F., Farci, P., Hadziyannis, S., Jin, R., Lu, Z.-M., Piratvisuth, T., Germanidis, G., Yurdaydin, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040431 · Cited by 1,145
LAMIVUDINE AS INITIAL TREATMENT FOR CHRONIC HEPATITIS B IN THE UNITED STATES
Ules, J., Ienstag, L. D., Chiff, E. U. R. S., Right, L. W., Errillo, R. O. P. P., Ann, L. H., Rowther, L. Y. C., Ondreay, D. C., Oessner, M. A. W., Ubin, M. A. R., et al. (1999) · Cited by 1,116
Adinolfi, L. E., Gambardella, M., Andreana, A., Tripodi, M.-F., Utili, R., & Ruggiero, G. (2001) · Hepatology · doi:10.1053/jhep.2001.24432 · Cited by 1,059
Enomoto, N., Sakuma, I., Asahina, Y., Kurosaki, M., Murakami, T., Yamamoto, C., Ogura, Y., Izumi, N., Marumo, F., & Sato, C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601113340203 · Cited by 998
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Wong, D. K. H., Cheung, A. M., O'Rourke, K., Naylor, C. D., Detsky, A. S., & Heathcote, J. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-4-199308150-00011 · Cited by 984
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.020 · Cited by 881
Chung, R. T., Andersen, J., Volberding, P., Robbins, G. K., Liu, T., Sherman, K. E., Peters, M. G., Koziel, M. J., Bhan, A. K., Alston, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032653 · Cited by 875
Peginterferon Alfa-2b and Ribavirin for 12 vs. 24 Weeks in HCV Genotype 2 or 3
Mangia, A., Santoro, R., Minerva, N., Ricci, G. L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042608 · Cited by 840
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Lindsay, K., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C., Jacobson, I. M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008023230503 · Cited by 840
Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., & Albrecht, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50364 · Cited by 819
Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B
Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., & Häussinger, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342202 · Cited by 803
Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B
Lai, C.-L., Gane, E., Liaw, Y.-F., Hsu, C.-W., Thongsawat, S., Wang, Y., Chen, Y., Heathcote, E. J., Rasenack, J., Bzowej, N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066422 · Cited by 773
Shintani, Y., Fujie, H., Miyoshi, H., Tsutsumi, T., Tsukamoto, K., Kimura, S., Moriya, K., & Koike, K. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.056 · Cited by 763
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c
Poynard, T., Ratziu, V., Charlotte, F., Goodman, Z., McHutchison, J., & Albrecht, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00097-0 · Cited by 749
Romero-Gómez, M., Del Mar Viloria, M., Andrade, R. J., Salmerón, J., Diago, M., Fernández-Rodríguez, C. M., Corpas, R., Cruz, M., Grande, L., Vázquez, L., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.12.049 · Cited by 732
Interferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Leung, N. W. Y., Lai, C.-L., Chang, T.-T., Guan, R., Lee, C.-M., Ng, K.-Y., Lim, S.-G., Wu, P.-C., Dent, J. C., Edmundson, S., et al. (2001) · Hepatology · doi:10.1053/jhep.2001.25084 · Cited by 626
Poynard, T., Ratziu, V., McHutchison, J., Manns, M., Goodman, Z., Zeuzem, S., Younossi, Z., & Albrecht, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50267 · Cited by 604
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3
Rubbia-Brandt, L., Quadri, R., Abid, K., Giostra, E., Malé, P.-J., Mentha, G., Spahr, L., Zarski, J.-P., Borisch, B., Hadengue, A., et al. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80166-x · Cited by 593
Muir, A. J., Bornstein, J. D., & Killenberg, P. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032502 · Cited by 541
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Ma, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042957 · Cited by 531
EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B
Jury, T. E. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00378-7 · Cited by 512
Chronic hepatitis B: Update of recommendations† ‡
Lok, A. S. F., & McMahon, B. J. (2004) · Hepatology · doi:10.1002/hep.20110 · Cited by 500
Peginterferon Alfa-2a and Ribavirin for 16 or 24 Weeks in HCV Genotype 2 or 3
Shiffman, M. L., Suter, F., Bacon, B. R., Nelson, D., Harley, H., Solá, R., Shafran, S. D., Barange, K., Lin, A., Soman, A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066403 · Cited by 493
Cooksley, W. G. E., Piratvisuth, T., Lee, S. ‐., Mahachai, V., Chao, Y. ‐., Tanwandee, T., Chutaputti, A., Chang, W. Y., Zahm, F. E., & Pluck, N. (2003) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00450.x · Cited by 475
Conjeevaram, H. S., Fried, M. W., Jeffers, L. J., Terrault, N. A., Wiley–Lucas, T. E., Afdhal, N., Brown, R. S., Belle, S. H., Hoofnagle, J. H., Kleiner, D. E., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.06.008 · Cited by 472
Chen, L., Borozan, I., Feld, J., Sun, J., Tannis, L.-L., Coltescu, C., Heathcote, J., Edwards, A. M., & McGilvray, I. D. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.059 · Cited by 453
LAI, C., LEUNG, N., TEO, E., TONG, M., WONG, F., HANN, H., HAN, S., POYNARD, T., MYERS, M., & CHAO, G. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.053 · Cited by 449
ZEUZEM, S. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.02.007 · Cited by 448
Lok, A. S., Zoulim, F., Locarnini, S., Bartholomeusz, A., Ghany, M. G., Pawlotsky, J.-M., Liaw, Y.-F., Mizokami, M., & Kuiken, C. (2007) · Hepatology · doi:10.1002/hep.21698 · Cited by 447
Benhamou, Y., Bochet, M., Thibault, V., Di Martino, V., Caumes, E., Bricaire, F., Opolon, P., Katlama, C., & Poynard, T. (1999) · Hepatology · doi:10.1002/hep.510300525 · Cited by 424
Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B
Hoofnagle, J. H., Peters, M., Mullen, K. D., Jones, D. B., Rustgi, V., Di Bisceglie, A., Hallahan, C., Park, Y., Meschievitz, C., & Jones, E. A. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90367-8 · Cited by 420
Sánchez-Tapias, J. M., Costa, J., Mas, A., Bruguera, M., & Rodés, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.37041 · Cited by 415
Host genetic factors influence disease progression in chronic hepatitis C
Powell, E. E., Edwards-Smith, C. J., Hay, J. L., Clouston, A. D., Crawford, D. H., Shorthouse, C., Purdie, D. M., & Jonsson, J. R. (2000) · Hepatology · doi:10.1053/he.2000.6253 · Cited by 398
Poynard, T., McHutchison, J., Goodman, Z., Ling, M.-H., & Albrecht, J. (2000) · Hepatology · doi:10.1002/hep.510310131 · Cited by 368
Lefkowitch, J. H., Schiff, E. R., Davis, G. L., Perrillo, R. P., Lindsay, K., Bodenheimer, H. C., Balart, L. A., Ortego, T. J., Payne, J., Dienstag, J. L., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90432-c · Cited by 368
Steatosis in chronic hepatitis C: Relative contributions of obesity, diabetes mellitus, and alcohol
Monto, A., Alonzo, J., Watson, J. J., Grunfeld, C., & Wright, T. L. (2002) · Hepatology · doi:10.1053/jhep.2002.35064 · Cited by 361
Bressler, B. L., Guindi, M., Tomlinson, G., & Heathcote, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50350 · Cited by 358
Iron and Chronic Viral Hepatitis
Bonkovsky, H. L., Banner, B. F., & Rothman, A. L. (1997) · Hepatology · doi:10.1002/hep.510250345 · Cited by 335
Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
Lam, N. P., Neumann, A. U., Gretch, D. R., Wiley, T. E., Perelson, A. S., & Layden, T. J. (1997) · Hepatology · doi:10.1002/hep.510260130 · Cited by 329
Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis
Czaja, A. J., & Carpenter, H. A. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91081-r · Cited by 324
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B
van Zonneveld, M., Honkoop, P., Hansen, B. E., Niesters, H. G. M., Murad, S. D., de Man, R. A., Schalm, S. W., & Janssen, H. L. A. (2004) · Hepatology · doi:10.1002/hep.20128 · Cited by 322
Jacobson, I. M., Brown, R. S., Freilich, B., Afdhal, N., Kwo, P. Y., Santoro, J., Becker, S., Wakil, A. E., Pound, D., Godofsky, E., et al. (2007) · Hepatology · doi:10.1002/hep.21932 · Cited by 304
Racial differences in responses to therapy with interferon in chronic hepatitis C
Reddy, R. K., Hoofnagle, J. H., Tong, M. J., Lee, W. M., Pockros, P., Heathcote, J. E., Albert, D., & Joh, T. (1999) · Hepatology · doi:10.1002/hep.510300319 · Cited by 291
Mommeja-Marin, H., Mondou, E., Blum, R. M., & Rousseau, F. (2003) · Hepatology · doi:10.1053/jhep.2003.50208 · Cited by 275
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a
Zeuzem, S., Lee, J., Herrmann, E., Fricke, J., Neumann, A. U., Modi, M., Colucci, G., & Roth, W. K. (2001) · Gastroenterology · doi:10.1053/gast.2001.24006 · Cited by 270
Pearlman, B. L., Ehleben, C., & Saifee, S. (2007) · Hepatology · doi:10.1002/hep.21919 · Cited by 269
Feld, J. J., Nanda, S., Huang, Y., Chen, W., Cam, M., Pusek, S. N., Schweigler, L. M., Theodore, D., Zacks, S. L., Liang, J. T., et al. (2007) · Hepatology · doi:10.1002/hep.21853 · Cited by 265
Flink, H. J., van Zonneveld, M., Hansen, B. E., de Man, R. A., Schalm, S. W., Janssen, H. L. A., & for the HBV 99-01 Study Group* (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00418.x · Cited by 262
Olynyk, J. K., Reddy, K. R., di Bisceglie, A. M., Jeffers, L. J., Parker, T. I., Radick, J. L., Schiff, E. R., & Bacon, B. R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90209-0 · Cited by 254
Host- and disease-specific factors affecting steatosis in chronic hepatitis C
Czaja, A. J., Carpenter, H. A., Santrach, P. J., & Breanndan Moore, S. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80004-4 · Cited by 248
Papatheodoridis, G. V., Manesis, E., & Hadziyannis, S. J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00094-5 · Cited by 246
Fracanzani, A. (2001) · Hepatology · doi:10.1053/jhep.2001.22506 · Cited by 245
A controlled trial of interferon with or without prednisone priming for chronic hepatitis B
Lok, A. S. F., Wu, P.-C., Lai, C.-L., Lau, J. Y. N., Leung, E. K. Y., Wong, L. S. K., Ma, O. C. K., Lauder, I. J., Ng, C. P. L., & Chung, H.-T. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90337-x · Cited by 242
Fried, M. W., Piratvisuth, T., Lau, G. K. K., Marcellin, P., Chow, W.-C., Cooksley, G., Luo, K.-X., Paik, S. W., Liaw, Y.-F., Button, P., et al. (2008) · Hepatology · doi:10.1002/hep.22065 · Cited by 235
Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
Zeuzem, S., Schmidt, J. M., Lee, J., Ruster, B., & Roth, W. K. (1996) · Hepatology · doi:10.1002/hep.510230225 · Cited by 234
Contribution of obesity to hepatitis C-related fibrosis progression
Ortiz, V (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04352-6 · Cited by 233
&NA; (2001) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200104000-00030 · Cited by 232
Pawlotsky, J., Dusheiko, G., Hatzakis, A., Lau, D., Lau, G., Liang, T. J., Locarnini, S., Martin, P., Richman, D. D., & Zoulim, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.036 · Cited by 230
Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B
Manesis, E. K., & Hadziyannis, S. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.25524 · Cited by 216
Determinants for Sustained Hbeag Response to Lamivudine Therapy
Chien, R.-N., Yeh, C.-T., Tsai, S.-L., Chu, C.-M., & Liaw, Y.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50458 · Cited by 214
D'Souza, R., Sabin, C. A., & Foster, G. R. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41403.x · Cited by 212
Response to interferon α therapy is influenced by the iron content of the liver
Van Thiel, D. H., Friedlander, L., Fagiuoli, S., Wright, H. I., Irish, W., & Gavaler, J. S. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(94)80017-0 · Cited by 209
Farci, P., Strazzera, R., Alter, H. J., Farci, S., Degioannis, D., Coiana, A., Peddis, G., Usai, F., Serra, G., Chessa, L., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052712599 · Cited by 200
Impact of steatosis on progression of fibrosis in patients with mild hepatitis C
Fartoux, L., Chazouillères, O., Wendum, D., Poupon, R., & Serfaty, L. (2005) · Hepatology · doi:10.1002/hep.20519 · Cited by 192
Chan, H. L. Y., Heathcote, E. J., Marcellin, P., Lai, C.-L., Cho, M., Moon, Y. M., Chao, Y.-C., Myers, R. P., Minuk, G. Y., Jeffers, L., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-11-200712040-00183 · Cited by 192
Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation
Hwang, S., Luo, J., Chu, C., Lai, C., Lu, C., Tsay, S., Wu, J., Chang, F., & Lee, S. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2001.02407.x · Cited by 187
Romero-Gómez, M., Fernández-Rodríguez, C. M., Andrade, R. J., Diago, M., Alonso, S., Planas, R., Solá, R., Pons, J. A., Salmerón, J., Barcena, R., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.022 · Cited by 185
Genotype‐specific mechanisms for hepatic steatosis in chronic hepatitis C infection
Hui, J. M., Kench, J., Farrell, G. C., Lin, R., Samarasinghe, D., Liddle, C., Byth, K., & George, J. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02813.x · Cited by 178
Race, insulin resistance and hepatic steatosis in chronic hepatitis C
Conjeevaram, H. S., Kleiner, D. E., Everhart, J. E., Hoofnagle, J. H., Zacks, S., Afdhal, N. H., & Wahed, A. S. (2007) · Hepatology · doi:10.1002/hep.21455 · Cited by 176
Veldt, B. J., Saracco, G., Boyer, N., Cammà, C., Bellobuono, A., Hopf, U., Castillo, I., Weiland, O., Nevens, F., Hansen, B. E., et al. (2004) · Gut · doi:10.1136/gut.2003.038257 · Cited by 174
Alcohol Use and Treatment of Hepatitis C Virus: Results of a National Multicenter Study
Anand, B. S., Currie, S., Dieperink, E., Bini, E. J., Shen, H., Ho, S. B., & Wright, T. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.02.023 · Cited by 162
Mechanisms of Synergy Between Alcohol and Hepatitis C Virus
Singal, A. K., & Anand, B. S. (2007) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3180381584 · Cited by 152
Iron, oxidative stress and liver fibrogenesis
Pietrangelo, A. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80368-1 · Cited by 140
Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy
Liaw, Y. (2006) · Antiviral Therapy · doi:10.1177/135965350601100614 · Cited by 126
Taylor, M. W., Tsukahara, T., Brodsky, L., Schaley, J. E., Sanda, C., Stephens, M. J., McClintick, J. N., Edenberg, H. J., Li, L., Tavis, J. E., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02640-06 · Cited by 122
Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response
Yuen, M., Fong, D., Wong, D. K.-H., Yuen, J. C., Fung, J., & Lai, C. (2007) · Hepatology · doi:10.1002/hep.21939 · Cited by 118
Iron stores, response to α‐interferon therapy, and effects of iron depletion in chronic hepatitis C
Piperno, A., Sampietro, M., D’Alba, R., Roffi, L., Fargion, S. R., Parma, S., Nicoli, C., Corbetta, N., Pozzi, M., Arosio, V., et al. (1996) · Liver International · doi:10.1111/j.1600-0676.1996.tb00737.x · Cited by 116
Buster, E. H. C. J., Hansen, B. E., Buti, M., Delwaide, J., Niederau, C., Michielsen, P. P., Flisiak, R., Zondervan, P. E., Schalm, S. W., & Janssen, H. L. A. (2007) · Hepatology · doi:10.1002/hep.21723 · Cited by 115
Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C Genotype 4
Hasan, F. A., Asker, H., Al-Khaldi, J., Siddique, I., Al-Ajmi, M., Owaid, S., Varghese, R., & Al‐Nakib, B. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.40077.x · Cited by 113
Differences in treatment outcome for hepatitis C among ethnic groups
Hepburn, M. J., Hepburn, L. M., CANTU, N., Lapeer, M. G., & Lawitz, E. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.02.043 · Cited by 106
Khuroo, M. S., Khuroo, M. S., & Dahab, S. T. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02208.x · Cited by 103
Bárbaro, G., Lorenzo, G. D., Ribersani, M., Soldini, M., Giancaspro, G., Bellomo, G., Belloni, G., Grisorio, B., & Barbarini, G. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80128-7 · Cited by 101
Bonkovsky, H. L., Naishadham, D., Lambrecht, R. W., Chung, R. T., Hoefs, J. C., Nash, S. R., Rogers, T. E., Banner, B. F., Sterling, R. K., Donovan, J. A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.036 · Cited by 97
Missiha, S. B., Heathcote, J., Arenovich, T., Khan, K., & The Canadian Pegasys Expanded Access Group (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01431.x · Cited by 90
Role of γ‐glutamyl transferase activity in patients with chronic hepatitis C virus infection
SILVA, I. S., FERRAZ, M. L. C., Perez, R. D. M., Lanzoni, V. P., Figueiredo, V. M., & SILVA, A. E. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2003.03256.x · Cited by 84
Layden, J. E., Layden, T. J., Reddy, K. R., Levy‐Drummer, R. S., Poulakos, J. J., & Neumann, A. U. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00377.x · Cited by 80
Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C
Kaserer, Fiedler, Steindl, Müller, E., Wrba, & Ferenci (1998) · Histopathology · doi:10.1046/j.1365-2559.1998.00413.x · Cited by 78
Sarrazin, C., Berg, T., Lee, J.-H., Teuber, G., Dietrich, C. F., Roth, W. K., & Zeuzem, S. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80253-0 · Cited by 77
Self-citationZhao, H., Kurbanov, F., Wan, M.-B., Yin, Y.-K., Niu, J. Q., Hou, J., Wei, L., Wang, G. ‐., Tanaka, Y., Mizokami, M., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511042 · Cited by 76
Piperno, A., Fargion, S. R., D’Alba, R., Roffi, L., Fracanzani, A. L., Vecchi, L., Failla, M., & Fiorelli, G. (1992) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80671-3 · Cited by 73
Distante, S., Bjøro, K., Hellum, K. B., Myrvang, B., Berg, J. P., Skaug, K., Raknerud, N., & Bell, H. (2002) · Liver International · doi:10.1046/j.0106-9543.2002.01672.x · Cited by 70
Lee, C., Ong, G.-Y., Lu, S., Wang, J., Liao, C., Tung, H., Chen, T.-M., & Changchien, C. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00267-2 · Cited by 69
Liver iron influences the response to interferon alpha therapy in chronic hepatitis C
Fargion, S. R., Fracanzani, A. L., Sampietro, M., Molteni, V., Boldorini, R. L., Mattioli, M., Cesana, B. M., Lunghi, G., Piperno, A., Valsecchi, C., et al. (1997) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199705000-00016 · Cited by 66
Cindoruk, M., Karakan, T., & Ünal, S. (2007) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000225586.78330.60 · Cited by 65
Hatakeyama, T., Noguchi, C., Hiraga, N., Mori, N., Tsuge, M., Imamura, M., Takahashi, S., Kawakami, Y., Fujimoto, Y., Ochi, H., et al. (2007) · Hepatology · doi:10.1002/hep.21581 · Cited by 64
HOFER, H. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.02.030 · Cited by 64
Puchhammer‐Stöckl, E., Mandl, C. W., Kletzmayr, J., Holzmann, H., Hofmann, A., Aberle, S. W., Heinz, F.-X., Watschinger, B., & Hofmann, H. (2000) · The Journal of Infectious Diseases · doi:10.1086/315519 · Cited by 60
Hepatic iron contents and response to interferon-α in patients with chronic hepatitis C
Izumi, N., Enomoto, N., Uchihara, M., et al. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02091542 · Cited by 57
Hom, X. B., Little, N. R., Gardner, S. D., & Jonas, M. M. (2004) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000126412.93562.f5 · Cited by 54
Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C
Lebray, P., Zylberberg, H., Hüe, S., Poulet, B., Carnot, F., Martin, S., Chrétien, Y., Pol, S., Caillat‐Zucman, S., Bréchot, C., et al. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00488.x · Cited by 52
Gehrke, S. G., Stremmel, W., Mathes, I., Riedel, H.-D., Bents, K., & Kallinowski, B. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0493-0 · Cited by 47
Layden, T. J., Layden, J. E., Reddy, K. R., Levy‐Drummer, R. S., Poulakos, J. J., & Neumann, A. U. (2002) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2002.00376.x · Cited by 43
Jorquera, F., Monte, M. J., GUERRA, J., Sánchez‐Campos, S., MERAYO, J. A., Olcoz, J. L., González‐Gallego, J., & Marín, J. J. G. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03725.x · Cited by 36
Marcellin, P., Jacobson, I. M., Habersetzer, F., Şentürk, H., Andreoné, P., Moyes, C. D., Horban, A., Teuber, G., Sorbel, J., Anderson, J., et al. (2008) · Journal of Hepatology · doi:10.1016/s0168-8278(08)60059-8 · Cited by 35
Kageyama, F., Kobayashi, Y., Murohisa, G., et al. (1998) · Biological Trace Element Research · doi:10.1007/bf02783335 · Cited by 22
Cited by
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Rauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T., Bochud, M., Battegay, M., Bernasconi, E., Borovicka, J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.056 · Cited by 1,137
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.023 · Cited by 1,088
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
Scheel, T. K. H., & Rice, C. M. (2013) · Nature Medicine · doi:10.1038/nm.3248 · Cited by 554
Metadata
- Authors
- Kau, A., Vermehren, J., & Sarrazin, C.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 49
- Issue
- 4
- Pages
- 634-651
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2116047701
- Cited by
- 324
- References
- 130
- FWCI
- 21.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.